2nd ADC Pharmacokinetics and Clinical Pharmacology Summit | December 9-11, 2025 | Boston, MA

As ADC approvals grow and pipelines expand, dose selection has become one of the field’s biggest challenges, and Project Optimus has resulted in pushing developers to move beyond maximum tolerated dose and define regimens that truly balance safety and efficacy.

Increasingly complex ADC design only amplifies these challenges; bispecifics, dual payloads, and combination regimens are all contributing to increased scrutiny and effect on PKPD profiles and clinical pharmacology.

The 2nd ADC Pharmacokinetics and Clinical Pharmacology Summit brings together experts in PKPD, bioanalysis, pharmacometrics, and clinical pharmacology to share novel data and real-world case studies. Collaborate with 60+ colleagues across biotech, pharma, and academia in a focused environment to exchange knowledge, refine dose strategies, and accelerate the delivery of safe, effective ADCs to patients.


URLs:
Brochure: https://go.evvnt.com/3223384-0?pid=2874
Website: https://go.evvnt.com/3223384-1?pid=2874

Category: Conferences | Science, Health & Medicine

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,
Drug Developer - Conference Only: USD 2999.00,
Academic - Conference + Workshops Day: USD 3597.00,
Academic - Conference Only: USD 2599.00,
Solution Provider - Conference + Workshop Day: USD 5097.00,
Solution Provider - Conference Only: USD 3699.00

Speakers: Abhishek Sathe, Associate Director, Clinical Pharmacology, Gilead, Amit Khatri, Senior Director, Daiichi Sankyo, Ashish Thakur, Director, DMPK, Oncology, AstraZeneca, Chris Beaver, Executive Director, Global Head of Regulated Bioanalysis, Daiichi Sankyo, Christina Vasalou, Senior Director, AstraZeneca, Edward LaGory, Senior Principal Scientist, Amgen, Eshita Khera, Principal Scientist II, Novartis BioMedical Research, Frank Richard, Vice President - Medical, Heidelberg Pharma, Hongmei Xu, Vice President, Head of Quantitative Pharmacology, Bicycle Therapeutics plc , Marcel Hop, Vice President and Lead of DMPK, Genentech, Nicole Wilski, Senior Scientist, Tavotek, Niresh Hariparsad, Senior Director, AstraZeneca, Ping Chang, Researcher, University at Buffalo , Prabhas Jagdale, Principal Scientist - Pharmacokinetic Pharmacodynamic Modelling, GlaxoSmithKline, Rakesh Dixit, CEO and Founder, Bionavigen, Salaheldin Hamed, Director, Clinical Pharmacology Oncology (Cell Therapy and Biologics), Astellas Pharma, Werner Rubas, Vice President, Principal Development, Sutro Biopharma , Yuting Wang, Senior Scientist, AbbVie